Physician profile
Wei Fan
NPI 1013273606
$4,382.09
in general payments reported to CMS, 2019-2025
22 companies · $800 in 2025
The $800 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $648 · 2020: $145 · 2021: $257 · 2022: $201 · 2023: $1,196 · 2024: $1,135 · 2025: $800.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,120 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,119.70 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,442.62 | 2019-2025 | Breztri, Farxiga, Airsupra |
| Gilead Sciences, INC. | $830.51 | 2022-2025 | Vemlidy |
| Amgen INC. | $371.63 | 2020-2025 | Evenity, Krystexxa, Prolia |
| Novo Nordisk INC | $327.78 | 2019-2025 | Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $300.62 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Sunovion Pharmaceuticals INC. | $215.11 | 2019 | |
| Dexcom, INC. | $134.89 | 2023 | Dexcom G7 Gss (161) |
| Pfizer INC. | $106.04 | 2021-2024 | |
| Lilly USA, LLC | $100.20 | 2021-2023 | Jardiance, Emgality |
| Exact Sciences Corporation | $86.43 | 2023-2025 | Cologuard Collection Kit |
| Vertos Medical, INC. | $77.74 | 2019 | |
| Merck Sharp & Dohme LLC | $62.28 | 2020-2025 | Capvaxive, Gardasil 9, Gardasil |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.43 | 2023-2025 | Jardiance |
| Astellas Pharma US INC | $44.79 | 2024-2025 | Veozah |
| Novartis Pharmaceuticals Corporation | $42.58 | 2019 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $42.45 | 2024-2025 | |
| Sanofi Pasteur INC. | $39.21 | 2023-2024 | |
| Abbott Laboratories | $37.02 | 2023 | Freestyle Libre 3 |
| Inspire Medical Systems, INC. | $31.28 | 2025 | Inspire |
| Abbvie INC. | $14.79 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.51 | 2025 | Zoryve |
| Phathom Pharmaceuticals, INC. | $14.18 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Wei Fan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.